Bayer's Vitrakvi On Track To Become EU’s First Tumor-Agnostic Cancer Treatment

 
• By Vibha Sharma
  
Generate a summary of this article
Listen to this article
Beta

Five new medicines, including what could become Europe’s first ever tumor-agnostic cancer treatment, have been recommended for approval by the European Medicines Agency.

Larotrectinib
Vitrakvi Is First Tumor-Agnostic Treatment Recommended For Pan-EU Approval • Source: Shutterstock

The European Medicines Agency this week recommended granting EU-wide marketing approval for five new medicines, including Bayer's anticancer drug Vitrakvi (larotrectinib) and GW Pharmaceuticals' plant-derived cannabidiol product, Epidyolex, for treating seizures associated with two forms of epilepsy, Lennox-Gastaut syndrome or Dravet syndrome .

The other recommendations were for Theratechnologies' Trogarzo (ibalizumab), for the treatment of HIV infection, Acorda Therapeutics' Inbrija (levodopa),...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     
    • By Anabel Costa-Ferreira and Ian Schofield

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography